MedImpact Achieves Record-Low Trend
Commercial plans realize the lowest drug spend to date — with only a 1.6 percent increase
MedImpact released its 2017 Annual Trend Report — reavealing record-low trend results in 2017 — at its Annual Conference last week in San Diego. In spite of rising drug prices for established drugs and blockbuster innovator drugs, MedImpact achieved record-low drug trend across commercial, Medicare and Medicaid lines of business in 2017.
Commercial plans saw the lowest trend increase — just 1.6% compared to 2.9% in 2016. Unsurprisingly, commercial specialty trend was 10.2% in 2017, representing only 1% of claim volume, but accounting for 41% of total spend.
With the impact of recent merger and acquisition activities and high-impact, high-cost specialty and orphan drugs dominating the drug pipeline, plan sponsors contend with numerous, competing market dynamics impacting budgets across both the pharmacy and medical benefits, including:
The 2017 Annual Trend Report details MedImpact’s success at managing trend in the face of rising drug costs, providing critical data and industry insights — and advanced trend management solutions to help drive low-net cost and lower prescription drug costs.